Evidence map›Paper›PMID 27600041›Full record

ArticleAntimicrobial agents and chemotherapy2016

Antileishmanial Activity of Ezetimibe: Inhibition of Sterol Biosynthesis, In Vitro Synergy with Azoles, and Efficacy in Experimental Cutaneous Leishmaniasis.

Valter Viana Andrade-Neto, Edézio Ferreira Cunha-Júnior, Marilene Marcuzzo do Canto-Cavalheiro, Geórgia Correa Atella, Talita de Almeida Fernandes, Paulo Roberto Ribeiro Costa, Eduardo Caio Torres-Santos

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Microorganisms · 2025
    Article
  3. Article
  4. Article
  5. Approved drugs successfully repurposed againstFrontiers in cellular and infection microbiology · 2024
    Article
  6. Review
  7. Effect of 3-Carene and the Micellar Formulation onTropical medicine and infectious disease · 2023
    Article
  8. Article
  9. InhibitingPharmaceuticals (Basel, Switzerland) · 2023
    Article
  10. Article
  11. Homology Modeling,Frontiers in cellular and infection microbiology · 2022
    Article
  12. Unravelling the myth surrounding sterol biosynthesis as plausible target for drug design against leishmaniasis.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2021
    Review
  13. Ezetimibe blocksParasitology · 2021
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Valter Viana Andrade-NetoLaboratório de Bioquímica de Tripanosomatídeos, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brazil.
Edézio Ferreira Cunha-JúniorLaboratório de Bioquímica de Tripanosomatídeos, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brazil.
Marilene Marcuzzo do Canto-CavalheiroLaboratório de Bioquímica de Tripanosomatídeos, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brazil.
Geórgia Correa AtellaInstituto de Bioquímica Médica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Talita de Almeida FernandesLaboratório de Química Bioorgânica, Instituto de Pesquisas de Produtos Naturais, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Paulo Roberto Ribeiro CostaLaboratório de Química Bioorgânica, Instituto de Pesquisas de Produtos Naturais, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Eduardo Caio Torres-SantosLaboratório de Bioquímica de Tripanosomatídeos, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brazil ects@ioc.fiocruz.br.ORCID 0000-0003-2240-4519
Fundação Oswaldo Cruz · BRUniversidade Federal do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leishmaniasis affects mainly low-income populations in tropical regions. Radical innovation in drug discovery is time-consuming and expensive, imposing severe restrictions on the ability to launch new chemical entities for the treatment of neglected diseases. Drug repositioning is an attractive strategy for addressing a specific demand more easily. In this project, we have evaluated the antileishmanial activities of 30 drugs currently in clinical use for various morbidities. Ezetimibe, clinically used to reduce intestinal cholesterol absorption in dyslipidemic patients, killed Leishmania amazonensis promastigotes with a 50% inhibitory concentration (IC

Indexed as

AnimalsAzolesDisease Models, AnimalDrug Evaluation, PreclinicalDrug SynergismEzetimibeInhibitory Concentration 50Leishmania mexicanaLeishmaniasis, CutaneousMacrophages, PeritonealMice, Inbred BALB CSterolsTrypanocidal AgentsAzolesEzetimibeSterolsTrypanocidal Agents

Identifiers

PMID27600041
PMCPMC5075094
OpenAlexW2517552966

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.